Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel produc...

Novavax Inc (NVAX) has a valuation score of 60/100 (moderate), profitability score of 50/100 (moderate), financial health score of 78/100 (strong), Piotroski F-Score of 5/9, Altman Z-Score of -4.71 (distressed), revenue growth of -17.2% YoY.

Neutral

Analyst Consensus

Buy

Wall Street consensus estimates — not a PMP forecast · Updated Sep 1, 2026

Analyst Recommendations15 analysts · 2026-08-01
4
6
2
2
Strong Buy 4Buy 6Hold 2Sell 2Strong Sell 1

Recent Market Moves

See all NVAX moves →
DateSessionPriceMoveZ-Score
Aug 25Regular$9.44+6.55%4.36
Aug 25After-hours$9.44+6.55%4.36
Aug 19Pre-market$8.29+4.52%3.01
Aug 7Regular$7.97+3.04%2.02
Aug 4Regular$7.66+3.37%2.25